Navigation Links
Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Date:7/22/2009

ly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering. In addition, Trout Capital LLC acted as financial advisor to the Company. The offering was conducted as a public offering pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, New York 10020, or by calling (212) 356-0549.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect the actual future results of the Company and the trading price of securities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
4. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
6. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
7. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
8. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
9. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
10. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Holdings, Inc. (OTC Bulletin Board: ADLS ), announced ... discussing the Company,s 2010 fourth quarter and full-year financial results ... T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well ... an update on the Company. A press release reporting the ...
... March 17, 2011 Delta Point, Inc., a consulting ... business relationships, has named Ed Weimer as Executive Account ... for his ability to highly motivate, develop and inspire ... strategic vision to contribute to the organization,s goals. ...
... SHANGHAI, March 17, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... leading developer, manufacturer and distributor of probiotics products in ... categories of strain formula supplied to Bright Dairy. ... formulas that it supplies to Bright Dairy, one of ...
Cached Biology Technology:Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2China-Biotics Expands Product Supplied to Bright Dairy 2China-Biotics Expands Product Supplied to Bright Dairy 3
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... American College of Sports Medicine,s Conference on Integrative ... Miami, Florida. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the American College ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability ... disability that occurs when the regions of the ... , The use of non-invasive functional neuroimaging tools ... in dyslexia. However, most prior work has focused ... leaving a gap in our understanding of how ...
(Date:8/28/2014)... could pose a significant health risk to people with asthma ... of Allergy and Clinical Immunology . , By critically reviewing ... research has found that the presence of several types of ... well as increasing the likelihood of developing the condition. , ... University of Exeter Medical School and is the first time ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2
... A well-preserved fossil discovered in northeast China provides new ... species--the placental mammals. According to a paper published today ... new milestone in mammal evolution that was reached 35 million ... gap in the fossil record and helps to calibrate modern, ...
... This press release is available in French . ... the severity of brain damage after a stroke, according to a ... Jasna Kriz and Frdric Calon, showed that the extent of brain ... consumed DHA type omega-3s daily. Details of the study can be ...
... new method of single molecule DNA sequencing is being ... funding from the Biotechnology and Biological Sciences Research Council,s ... The aim of the research is to create novel ... strands. The human genome contains 3164.7 million nucleic ...
Cached Biology News:Fossil discovery represents new milestone in early mammal evolution 2Fossil discovery represents new milestone in early mammal evolution 3Omega-3s reduce stroke severity 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: